A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design.

Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One (2016) 0.81

Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. Medicine (Baltimore) (2015) 0.78

Effects of low-dose aspirin in subjects with dyslipidemia. Lipids Health Dis (2016) 0.75

A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study. BMJ Open (2015) 0.75

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care (2005) 30.41

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 26.64

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32

Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol (1991) 12.76

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet (1998) 10.42

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 7.34

Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet (2001) 6.38

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet (2012) 5.81

Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf (2010) 5.80

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10

Association of aspirin use with major bleeding in patients with and without diabetes. JAMA (2012) 4.94

Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc (2005) 2.70

Aspirin resistance. Lancet (2006) 2.54

Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol (2011) 2.40

Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry (2011) 1.89

Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer (2011) 1.70

Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med (2004) 1.70

Effects of physical activity on cardiovascular disease. Am J Cardiol (2011) 1.30

Lung cancer and incidence of stroke: a population-based cohort study. Stroke (2011) 1.27

Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf (1997) 1.20

Aspirin for primary prevention of cardiovascular disease events. Pharmacotherapy (2012) 0.90

The aspirin controversy in primary prevention. Curr Opin Cardiol (2012) 0.88

Are we ready to recommend aspirin for cancer prevention? Lancet (2012) 0.88

Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother (2005) 0.88

Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. Handb Exp Pharmacol (2012) 0.87

Liver cirrhosis and risk of intracerebral hemorrhage: a 9-year follow-up study. Stroke (2011) 0.85

Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? JAMA (2012) 0.84

Benefits and risks of aspirin use. JAMA (2012) 0.80

Sugar restriction: the evidence for a drug-free intervention to reduce cardiovascular disease risk. Intern Med J (2012) 0.79

ACP Journal Club. Review: Aspirin does not reduce CHD or cancer mortality but increases bleeding. Ann Intern Med (2012) 0.78

Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. J Atheroscler Thromb (2012) 0.78

Antiplatelet treatment in primary and secondary stroke prevention in women. Eur J Intern Med (2012) 0.77

Caffeine-containing medicines increase the risk of hemorrhagic stroke. Stroke (2013) 0.77